Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.51 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173466 | 0.93 | NR1H4 (0.58) | NR1H4PPARGPPARAPPARDEPHX2 | |
| SCHEMBL6172764 | 0.85 | NR1H4 (0.64) | NR1H4PPARGPPARARXFP2ESR1 | |
| SCHEMBL6172523 | 0.84 | RXFP1 (0.55) | NR1H4PPARGPPARAPPARD | |
| SCHEMBL6170072 | 0.82 | NR1H4 (0.47) | NR1H4PPARGPPARAPPARDEPHX2 | |
| SCHEMBL6168239 | 0.82 | NR1H4 (0.47) | NR1H4PPARGPPARAPPARDEPHX2 | |
| SCHEMBL6173478 | 0.80 | F10 (0.47) | NR1H4PPARGPPARAEPHX2 | |
| SCHEMBL6171161 | 0.80 | NR1H4 (0.45) | NR1H4PPARGPPARAPPARDEPHX2 | |
| SCHEMBL6168019 | 0.79 | HPGD (0.50) | NR1H4PPARGPPARAPPARDEPHX2 | |
| SCHEMBL6170547 | 0.79 | MAPT (0.48) | NR1H4PPARGPPARAEPHX2 | |
| SCHEMBL6170664 | 0.78 | NR1H4 (0.43) | NR1H4PPARGPPARAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | NR1H4 1884/4885PPARG 3664/4885PPARA 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.